← Leaderboards
Charles S Lieber
Mount Sinai School Of Medicine Of Nyu
$6,244,965
Attributed
$6,244,965
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $863.2K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$6,244,965 · 7
By mechanism
R01$5,631,205 · 4
R21$366,185 · 1
R56$197,849 · 1
T32$49,726 · 1
Top collaborators
No co-investigators on record.
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Judith S Brook$26,759,186
- Giulio Maria Pasinetti$21,413,515
- Ali G Gharavi$45,808,576
- Richard C. Mohs$30,035,943
- David William Brook$3,136,004
Others in their field
Top investigators on “Phosphatidylcholines”
- David E Cohen · Yeshiva University$20,587,413
- Stanley L Hazen · Cleveland Clinic Foundation$13,171,664
- Rama K Mallampalli · Ohio State University$10,557,682
- Martin Conrad Carey · Brigham And Women'S Hospital$10,202,262
- Vytas A Bankaitis · University Of Alabama At Birmingham$9,410,305
- Jonathan Mark Brown · Wake Forest University Health Sciences$8,351,405
Research focus
PhosphatidylcholinesLiver CirrhosisSoybeansPlant ExtractsLiver Disorder ChemotherapyLaboratory RatAlcoholic Beverage ConsumptionFibrosisHuman TissueAntioxidantsCombination ChemotherapyHepatitis CInterferonsClinical ResearchRibavirinHepatitis C VirusHuman SubjectHuman Therapy EvaluationDisease /Disorder ModelDrug InteractionsFibrogenesisCytokineCollagenChemoprevention
Grant awards (26)
Synergistic Nutraceutical Effects of DLPC and SAMe$276,638
R01 · FY2007 · AT · contact PI
Antiviral/Antifibrotic Liver Therapy of Hepatitis C positive Alcohol Drinkers$38,873
R56 · FY2007 · AA · contact PI
DLPC Treatment of Alcoholic and Non-Alcoholic Fibrosis$305,889
R01 · FY2006 · AA · contact PI
Synergistic Nutraceutical Effects of DLPC and SAMe$278,205
R01 · FY2006 · AT · contact PI
Antiviral/Antifibrotic Liver Therapy of HCV+ Drinkers$158,976
R56 · FY2006 · AA · contact PI
Liver Fibrosis, Inflammation & Oxidative Stress Markers$120,135
R21 · FY2006 · AA · contact PI
DLPC Treatment of Alcoholic and Non-Alcoholic Fibrosis$311,746
R01 · FY2005 · AA
Synergistic Nutraceutical Effects of DLPC and SAMe$284,900
R01 · FY2005 · AT
Liver Fibrosis, Inflammation &Oxidative Stress Markers$123,025
R21 · FY2005 · AA
ANTIVIRAL &ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS$58,423
R01 · FY2005 · AA
ANTIVIRAL &ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS$571,650
R01 · FY2004 · AA
DLPC Treatment of Alcoholic and Non-Alcoholic Fibrosis$310,286
R01 · FY2004 · AA
Synergistic Nutraceutical Effects of DLPC and SAMe$284,900
R01 · FY2004 · AT
Liver Fibrosis, Inflammation &Oxidative Stress Markers$123,025
R21 · FY2004 · AA
ANTIVIRAL &ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS$509,738
R01 · FY2003 · AA
DLPC Treatment of Alcoholic and Non-Alcoholic Fibrosis$261,600
R01 · FY2003 · AA
DLPC Treatment of Alcoholic and Non-Alcoholic Fibrosis$47,268
R01 · FY2003 · AA
ANTIVIRAL &ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS$46,620
R01 · FY2003 · AA
ANTIVIRAL &ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS$494,892
R01 · FY2002 · AA
DLPC Treatment of Alcoholic and Non-Alcoholic Fibrosis$261,600
R01 · FY2002 · AA
ANTIVIRAL &ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS$480,478
R01 · FY2001 · AA
MECHANISM AND ROLE OF MICROSOMAL ETHANOL OXIDATION$54,575
R01 · FY2001 · AA
ANTIVIRAL &ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS$504,984
R01 · FY2000 · AA
DLPC TREATMENT OF ALCOHOLIC AND NON ALCOHOLIC FIBROSIS$223,601
R01 · FY2000 · AA
MECHANISM AND ROLE OF MICROSOMAL ETHANOL OXIDATION$63,212
R01 · FY2000 · AA
PATHOGENESIS AND TREATMENT OF ALCOHOL INDUCED DISEASES$49,726
T32 · FY2000 · AA